**Core Concept**
Myasthenia gravis is an autoimmune disease characterized by weakness and rapid fatigue of the muscles under voluntary control. The underlying pathophysiology involves the production of autoantibodies that impair the function of the neuromuscular junction, leading to a decrease in acetylcholine receptor (AChR) density and efficacy.

**Why the Correct Answer is Right**
The correct answer, **B. Acetylcholine receptors**, is the target of autoantibodies in myasthenia gravis patients. These autoantibodies are directed against the nicotinic acetylcholine receptors (nAChRs) on the postsynaptic muscle membrane. The presence of these autoantibodies leads to a decrease in the number of functional AChRs, resulting in impaired neurotransmission and muscle weakness. This is due to the activation of complement and the subsequent destruction of the AChRs, making it difficult for acetylcholine to bind and initiate muscle contraction.

**Why Each Wrong Option is Incorrect**
**Option A:** Acetylcholine is the neurotransmitter released by the motor neuron that binds to the AChR, but it is not the target of autoantibodies in myasthenia gravis.

**Option C:** Acetylcholine vesicles in the nerve terminal are involved in the release of acetylcholine, but they are not the target of autoantibodies in myasthenia gravis.

**Option D:** The actin-myosin complex of the muscle is involved in muscle contraction, but it is not the target of autoantibodies in myasthenia gravis.

**Clinical Pearl / High-Yield Fact**
Myasthenia gravis can be associated with thymoma, a type of tumor of the thymus gland, and patients with this condition may require thymectomy as part of their treatment.

**✓ Correct Answer: B. Acetylcholine receptors**